Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT)

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Feb 16, 2022

Keywords

ClinConnect Summary

Ventricular tachycardia (VT) is a potentially life-threatening arrhythmia characterized by electrical re-entry within patches of heterogeneous myocardial fibrosis leading to sustained consecutive ventricular beats at a rate \> 100 per minute. VT is classified based on hemodynamic stability, duration (less than or greater than 30 seconds), morphology (monomorphic or polymorphic), and mechanism (scar-related re-entry, automaticity, triggered activity.

In patients with monomorphic VT, implantable cardioverter-defibrillators (ICDs) have become the cornerstone of therapy in decreasing mortality...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age
• • Ishemic or non-ischemic cardiomyopathy
• • Recurrent episodes of monomorphic ventricular tachycardia having failed standard treatment with at least 1 antiarrhythmic drug
• • Previous endocardial and/or epicardial electrophysiology study and ablation.
• • Participants who have a contraindication to electrophysiology studies (ventricular thrombus, absence of vascular access, valvular heart disease or mechanical heart valve that precludes left-ventricular access) may be eligible for the protocol provided the arrhythmic substrate can be defined through non-invasive methods.
• Exclusion Criteria:
• • Previous RT in the treatment field that precludes furth RT
• • Active connective tissue disease
• • Interstitial pulmonary fibrosis
• • Pregnant or breastfeeding individuals
• • Participants who plan to become pregnant or breast feed during the study duration